Infinity Pharmaceuticals (NASDAQ:INFI) Now Covered by StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Infinity Pharmaceuticals (NASDAQ:INFI – Get Rating) in a report issued on Wednesday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, Piper Sandler reaffirmed a “neutral” rating on shares of Infinity Pharmaceuticals in a research report on Friday, February 24th.

Get Infinity Pharmaceuticals alerts:

Infinity Pharmaceuticals Price Performance

INFI stock opened at $0.19 on Wednesday. The stock has a market capitalization of $16.85 million, a P/E ratio of -0.39 and a beta of 1.36. The business has a 50-day moving average of $0.17 and a 200-day moving average of $0.37. Infinity Pharmaceuticals has a fifty-two week low of $0.12 and a fifty-two week high of $1.76.

Infinity Pharmaceuticals (NASDAQ:INFI – Get Rating) last posted its quarterly earnings data on Tuesday, March 28th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.01. The company had revenue of $0.54 million during the quarter, compared to analysts’ expectations of $11.88 million. Infinity Pharmaceuticals had a negative return on equity of 956.26% and a negative net margin of 1,608.46%. Equities analysts expect that Infinity Pharmaceuticals will post -0.46 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of INFI. Two Sigma Investments LP raised its stake in Infinity Pharmaceuticals by 84.2% in the fourth quarter. Two Sigma Investments LP now owns 44,738 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 20,449 shares during the period. Wittenberg Investment Management Inc. bought a new stake in Infinity Pharmaceuticals in the first quarter valued at approximately $28,000. Virtu Financial LLC raised its stake in Infinity Pharmaceuticals by 165.3% in the first quarter. Virtu Financial LLC now owns 176,529 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 109,992 shares during the period. Mirabella Financial Services LLP bought a new stake in Infinity Pharmaceuticals in the first quarter valued at approximately $34,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in Infinity Pharmaceuticals in the third quarter valued at approximately $61,000. 34.61% of the stock is owned by institutional investors and hedge funds.

Infinity Pharmaceuticals Company Profile

(Get Rating)

Infinity Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company, which engages in the business of developing novel medicines for people with cancer. It focuses on its drug development segment. The company was founded by Steven H. Holtzman and Matthew D. Shair on March 22, 1995 and is headquartered in Cambridge, MA.

Featured Stories

• Get a free copy of the StockNews.com research report on Infinity Pharmaceuticals (INFI)
• Is American Airlines a Good Stock to Buy?
• High Dividend REITs: Are They an Ideal Way to Diversify?
• It Is Not Too Late To “Git” On Board With GitLab 
• Is Frontline’s 20% Dividend Too Good To Be True?
• Hospitality’s Rebound Has A Table At Cracker Barrel

Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.